ATE204176T1 - Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven - Google Patents

Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven

Info

Publication number
ATE204176T1
ATE204176T1 AT92924246T AT92924246T ATE204176T1 AT E204176 T1 ATE204176 T1 AT E204176T1 AT 92924246 T AT92924246 T AT 92924246T AT 92924246 T AT92924246 T AT 92924246T AT E204176 T1 ATE204176 T1 AT E204176T1
Authority
AT
Austria
Prior art keywords
analogues
insulin
treatment
growth factors
optic nerve
Prior art date
Application number
AT92924246T
Other languages
English (en)
Inventor
Donna Bozyczko-Coyne
Nicola Neff
Michael E Lewis
Mohamed Iqbal
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Application granted granted Critical
Publication of ATE204176T1 publication Critical patent/ATE204176T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N57/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds
    • A01N57/18—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds
    • A01N57/20—Biocides, pest repellants or attractants, or plant growth regulators containing organic phosphorus compounds having phosphorus-to-carbon bonds containing acyclic or cycloaliphatic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/30—Phosphinic acids [R2P(=O)(OH)]; Thiophosphinic acids ; [R2P(=X1)(X2H) (X1, X2 are each independently O, S or Se)]
    • C07F9/301—Acyclic saturated acids which can have further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/28—Phosphorus compounds with one or more P—C bonds
    • C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3813—N-Phosphonomethylglycine; Salts or complexes thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/65—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
    • Y10S530/827—Proteins from mammals or birds
    • Y10S530/839—Nerves; brain

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Dentistry (AREA)
  • Plant Pathology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Pest Control & Pesticides (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Agronomy & Crop Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Environmental Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AT92924246T 1991-11-08 1992-11-03 Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven ATE204176T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79069091A 1991-11-08 1991-11-08
US07/963,329 US6310040B1 (en) 1991-11-08 1992-10-15 Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
PCT/US1992/009443 WO1993008826A1 (en) 1991-11-08 1992-11-03 Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs

Publications (1)

Publication Number Publication Date
ATE204176T1 true ATE204176T1 (de) 2001-09-15

Family

ID=27121062

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92924246T ATE204176T1 (de) 1991-11-08 1992-11-03 Verwendung von insulinähnlichen wachstumsfaktoren und analogen zur behandlung von erkrankungen der sehnerven

Country Status (9)

Country Link
US (1) US6310040B1 (de)
EP (1) EP0670729B1 (de)
JP (1) JP3445269B2 (de)
AT (1) ATE204176T1 (de)
CA (1) CA2122340C (de)
DE (1) DE69232008T2 (de)
DK (1) DK0670729T3 (de)
ES (1) ES2160581T3 (de)
WO (1) WO1993008826A1 (de)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs
AU693489B2 (en) * 1993-11-15 1998-07-02 Celtrix Pharmaceuticals, Inc. Method of treating neurological disorders
WO2001009327A2 (en) * 1999-07-28 2001-02-08 Genentech, Inc. Method of preventing the injury or death of retinal cells and treating ocular diseases
US5712249A (en) * 1994-09-08 1998-01-27 Ciba-Geigy Corporation Use of insulin-like growth factors I and II for inhibition of inflammatory response
WO1996007744A1 (en) * 1994-09-08 1996-03-14 Chiron Corporation A method of improved production of insulin-like growth factor
JP3191038B2 (ja) * 1996-06-26 2001-07-23 輝夫 西田 眼科用医薬組成物
US6514937B1 (en) 1997-02-25 2003-02-04 Celtrix Pharmaceuticals, Inc. Method of treating psychological and metabolic disorders using IGF or IGF/IGFBP-3
US6015786A (en) * 1997-02-25 2000-01-18 Celtrix Pharmaceuticals, Inc. Method for increasing sex steroid levels using IGF or IGF/IGFBP-3
US6025368A (en) * 1997-02-25 2000-02-15 Celtrix Pharmaceuticals, Inc. Method for treating the symptoms of chronic stress-related disorders using IGF
WO1998042369A1 (fr) * 1997-03-24 1998-10-01 Fujisawa Pharmaceutical Co., Ltd. Secretagogues de bile
US6121416A (en) * 1997-04-04 2000-09-19 Genentech, Inc. Insulin-like growth factor agonist molecules
US6420518B1 (en) 1997-04-04 2002-07-16 Genetech, Inc. Insulin-like growth factor agonist molecules
US6331523B1 (en) 1998-03-12 2001-12-18 Genentech, Inc. Method of enhancing the survival of retinal neurons and treating ocular diseases using FGF-5
US6875741B2 (en) 1998-09-02 2005-04-05 Renuka Pillutla Insulin and IGF-1 receptor agonists and antagonists
US7173005B2 (en) 1998-09-02 2007-02-06 Antyra Inc. Insulin and IGF-1 receptor agonists and antagonists
AU762351B2 (en) 1999-01-06 2003-06-26 Genentech Inc. Insulin-like growth factor (IGF) I mutant variants
AU3737500A (en) * 1999-03-12 2000-09-28 Genentech Inc. Method of preventing the death of retinal neurons and treating ocular diseases
GB9928323D0 (en) * 1999-11-30 2000-01-26 Cyclacel Ltd Peptides
US20050245451A1 (en) * 2000-04-05 2005-11-03 Pincus Matthew R Peptides selectively lethal to malignant and transformed mammalian cells
AU2001263215A1 (en) 2000-05-16 2001-11-26 Genentech Inc. Method for treating cartilage disorders
US7427598B2 (en) * 2000-05-31 2008-09-23 The United States Of Americas As Represented By The Secretary Of The Department Of Health And Human Services Post-natal administration of activity-dependent neurotrophic factor-derived polypeptides for enhancing learning and memory
DE60217066T4 (de) 2001-02-09 2010-07-01 Genentech, Inc., South San Francisco Kristallisierung von igf-1
US7714020B2 (en) 2001-05-24 2010-05-11 Neuren Pharmaceuticals Limited Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate
EP1401808B1 (de) 2001-05-24 2009-07-08 Neuren Pharmaceuticals Limited Gpe-analoga und peptidomimetika
US7605177B2 (en) 2001-05-24 2009-10-20 Neuren Pharmaceuticals Limited Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration
JP4253743B2 (ja) * 2001-12-03 2009-04-15 輝夫 西田 新規ペプチドおよびその医薬用途
TWI305778B (en) * 2001-12-03 2009-02-01 Nishida Teruo Peptides of an expressing unit for igf-i minimal activity and their pharmaceutical use
US20080103457A1 (en) * 2005-01-11 2008-05-01 Heart Failure Technologies, Inc. University Enterprise Laboratories (Uel) Method and System for Treating Heart Failure
EP1871796A4 (de) * 2005-04-20 2009-01-14 Auckland Uniservices Ltd Vesiculine
US8309057B2 (en) * 2005-06-10 2012-11-13 The Invention Science Fund I, Llc Methods for elevating neurotrophic agents
US20090169491A1 (en) * 2006-03-06 2009-07-02 Caregen Co., Ltd Peptides Having Activities of Insulin Like Growth Factor-1 and their Uses
EP2224961A1 (de) * 2007-11-26 2010-09-08 The Research Foundation of the State University of New York Kleinmolekülige krebsbehandlungen, die nekrose in krebszellen verursachen, aber normale zellen nicht angreifen
WO2009137721A2 (en) 2008-05-07 2009-11-12 Zystor Therapeutics, Inc. Lysosomal targeting peptides and uses thereof
BR112012000865A2 (pt) 2009-07-17 2019-09-24 T Tabor Aaron "composição e método para a modificação genética cosmética de células substancialmente intactas"
UA103104C2 (ru) 2009-07-22 2013-09-10 Ипсен Фарма С.А.С. Аналоги инсулиноподобного фактора роста-1 (igf-1), содержащие аминокислотную замену в положении 59
WO2011011073A1 (en) * 2009-07-22 2011-01-27 Ipsen Pharma S.A.S. Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1
TWI490371B (zh) 2009-07-28 2015-07-01 Industrie De Nora Spa 電解應用上的電極及其製法以及在電極表面上陽極釋氧之電解法和電冶法
WO2011071995A2 (en) 2009-12-08 2011-06-16 Case Western Reserve University Compounds and methods of treating ocular disorders
KR101669140B1 (ko) 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
WO2019195851A1 (en) 2018-04-06 2019-10-10 Oncolyze, Inc. Compositions for use in lysis of selective cancer cells
CN111763680A (zh) * 2019-05-22 2020-10-13 杭州杰迪生物科技有限公司 一种人胰岛素样生长因子-i或其类似物的制备方法、编码基因、表达载体及宿主细胞

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU598205B2 (en) * 1985-08-22 1990-06-21 Gropep Pty Ltd Peptide analogues of mammalian insulin-like growth factor-1
US4783524A (en) 1985-09-17 1988-11-08 Monsanto Company Growth factors
SE8505920D0 (sv) 1985-12-13 1985-12-13 Kabigen Ab New protein and its use
ATE112684T1 (de) 1987-04-28 1994-10-15 Boehringer Mannheim Gmbh Verwendung von igf-ii zur behandlung von knochenkrankheiten.
SE8703625D0 (sv) * 1987-09-18 1987-09-18 Kabivitrum Ab New medical use
EP0346429B1 (de) 1987-12-24 1994-12-28 Gropep Pty. Ltd. Peptid-analoge vom insulinähnlichen wachstums-faktor 1 (igf-1) oder faktor 2 (igf-2)
US5093317A (en) * 1989-06-05 1992-03-03 Cephalon, Inc. Treating disorders by application of insulin-like growth factor
US5652214A (en) * 1989-06-05 1997-07-29 Cephalon, Inc. Treating disorders by application of insulin-like growth factors and analogs
ES2101865T3 (es) * 1991-08-01 1997-07-16 Genentech Inc Igf-1 para mejorar el estado neural.
US6310040B1 (en) 1991-11-08 2001-10-30 Cephalon, Inc. Treating retinal neuronal disorders by the application of insulin-like growth factors and analogs

Also Published As

Publication number Publication date
DE69232008T2 (de) 2001-11-29
CA2122340C (en) 2007-06-12
EP0670729A4 (de) 1995-05-10
JP3445269B2 (ja) 2003-09-08
EP0670729B1 (de) 2001-08-16
CA2122340A1 (en) 1993-05-13
WO1993008826A1 (en) 1993-05-13
EP0670729A1 (de) 1995-09-13
ES2160581T3 (es) 2001-11-16
DK0670729T3 (da) 2001-12-10
DE69232008D1 (de) 2001-09-20
US6310040B1 (en) 2001-10-30
JPH07500839A (ja) 1995-01-26

Similar Documents

Publication Publication Date Title
DE69232008D1 (de) Verwendung von insulinähnlichen Wachstumsfaktoren und Analogen zur BEHANDLUNG VON ERKRANKUNGEN DER SEHNERVEN
CA2058443A1 (en) Treating Disorders by Application of Insulin-Like Growth Factors and Analogs
ATE112684T1 (de) Verwendung von igf-ii zur behandlung von knochenkrankheiten.
ATE82507T1 (de) Medizinische verwendung.
DE3779149D1 (de) Galanthamin oder dessen analoge zur behandlung der alzheimerschen krankheit.
ATE94069T1 (de) Verwendung von physiologisch wirksamen substanzen zur herstellung von medikamenten fuer gehirn- und nervenerkrankungen.
EP1039802A4 (de) Transdermale therapeutische vorrichtung mit capsaicin und seine analoga
ATE390932T1 (de) Verwendung von glp-1 oder analogen zur behandlung von myokardischem infarkt
NZ504026A (en) Methods for treating hypercoagulable states or acquired protein C deficiency using human-activated protein C
DE69203596D1 (de) Biologisch abbaubare und biologisch absorbierbare führungskanäle zur verwendung in der behandlung und regenerierung von nerven.
ATE105482T1 (de) Behandlung von krebs mit somatostatin und mit analogen davon.
ATE213411T1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
ATE338813T1 (de) Methode zur tumorbehandlung mit alloaktivierten humanen lymphozyen
AU587054B2 (en) Novel pharmaceutical compositions intended to the treatment of neuropathies and insuring the nervous regeneration
ATE220923T1 (de) Rekombinante adenoviren und deren verwendung in der gentherapie zur behandlung von augenerkrankungen
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE108658T1 (de) Verwendung von tetracycline zur herstellung eines arzneimittels zum herabsetzen des augendrucks.
ATE161725T1 (de) Verwendung von phosphatdiestern zur behandlung von erkrankungen der retina
US6174541B1 (en) Skin aging and wound treatment using cell migration agents
EP0515434A4 (en) Method for treating intestinal diseases
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
NO933742L (no) Humant, benavledet, insulinlignende vekstfaktorbindingsprotein
ATE306278T1 (de) Behandlung von knochenleiden mit adrenomedullin
DE69124382D1 (de) Authentischen igf-1 und hypokalorische menge von nährstoffen enthaltendes produkt und dessen verwendung zur behandlung kataboler zustände
ATE348589T1 (de) Verwendung von amylin, adrenomedullin und deren analoga zur behandlung von knorpeldefekten